HALISTER: Hep C Panel Will Consider Cost-Effectiveness in Guidelines

Hep C Panel Will Consider Cost-Effectiveness in Guidelines

Alert: HALISTER Source: BN (Bloomberg News)

Tickers GILD US (Gilead Sciences Inc) ABBV US (AbbVie Inc)

People Cara Miller (Gilead Sciences Inc) Steve Miller (Express Scripts Holding Co)

Topics Viral Hepatitis Infectious Diseases Viral Illnesses

To de-activate this alert, run {NLRT DEACT HALISTER <GO>}. To modify this alert, run {NLRT EDIT HALISTER <GO>}.

UUID: 7947283